Your browser is no longer supported. Please, upgrade your browser.
Evelo Biosciences, Inc.
Index- P/E- EPS (ttm)-2.51 Insider Own0.52% Shs Outstand46.17M Perf Week5.76%
Market Cap641.32M Forward P/E- EPS next Y-1.77 Insider Trans6.47% Shs Float42.89M Perf Month46.44%
Income-87.20M PEG- EPS next Q-0.50 Inst Own87.50% Short Float4.66% Perf Quarter159.02%
Sales- P/S- EPS this Y-39.70% Inst Trans0.00% Short Ratio6.09 Perf Half Y241.09%
Book/sh1.09 P/B12.64 EPS next Y19.90% ROA-88.80% Target Price15.50 Perf Year229.67%
Cash/sh- P/C- EPS next 5Y- ROE-159.20% 52W Range3.01 - 14.25 Perf YTD13.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High4.53% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low394.85% ATR1.26
Employees98 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)72.16 Volatility8.79% 12.48%
OptionableNo Debt/Eq0.59 EPS Q/Q32.80% Profit Margin- Rel Volume0.46 Prev Close13.78
ShortableYes LT Debt/Eq0.59 EarningsOct 29 BMO Payout- Avg Volume328.29K Price14.90
Recom2.40 SMA2025.87% SMA5086.99% SMA200176.34% Volume121,664 Change8.09%
Dec-23-20Initiated JMP Securities Mkt Outperform $27
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Jan-07-21 07:00AM  
Dec-23-20 10:07AM  
Dec-21-20 07:00AM  
Dec-14-20 11:21PM  
Dec-09-20 09:00AM  
Dec-03-20 07:00AM  
Nov-27-20 10:47AM  
Nov-10-20 09:41AM  
Nov-09-20 08:00AM  
Oct-29-20 07:00AM  
Oct-22-20 04:01PM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Oct-13-20 07:00AM  
Oct-12-20 09:00AM  
Sep-14-20 07:06AM  
Sep-08-20 07:00AM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jul-01-20 07:08AM  
Jun-24-20 07:56PM  
Jun-22-20 02:00AM  
Jun-16-20 07:00AM  
May-29-20 12:00PM  
May-28-20 08:00AM  
May-27-20 12:34PM  
May-14-20 02:58PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-04-20 09:00AM  
Apr-15-20 07:00AM  
Mar-05-20 07:00AM  
Mar-02-20 07:00AM  
Feb-25-20 12:09PM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-10-20 07:00AM  
Dec-20-19 06:39PM  
Dec-19-19 08:00AM  
Dec-05-19 07:00AM  
Nov-13-19 08:01AM  
Nov-08-19 07:00AM  
Nov-05-19 07:01AM  
Oct-29-19 08:00AM  
Sep-26-19 04:05PM  
Sep-20-19 07:00AM  
Sep-17-19 07:00AM  
Sep-03-19 08:00AM  
Aug-06-19 10:24PM  
Jul-30-19 08:00AM  
Jul-25-19 08:00AM  
Jul-15-19 08:00AM  
May-30-19 08:00AM  
May-27-19 10:29AM  
May-15-19 08:00AM  
May-08-19 02:23PM  
May-04-19 04:23PM  
May-02-19 07:00AM  
Apr-25-19 07:30AM  
Apr-03-19 08:00AM  
Mar-04-19 07:30AM  
Feb-14-19 07:00AM  
Feb-07-19 08:00AM  
Jan-28-19 06:00AM  
Jan-04-19 06:00AM  
Dec-05-18 08:00AM  
Nov-27-18 08:00AM  
Nov-26-18 08:00AM  
Nov-13-18 08:10AM  
Nov-07-18 08:00AM  
Nov-01-18 08:00AM  
Sep-06-18 08:00AM  
Aug-02-18 08:00AM  
Jun-25-18 08:00AM  
Jun-15-18 06:28PM  
Jun-14-18 08:00AM  
Jun-04-18 08:53AM  
May-31-18 08:00AM  
May-11-18 05:00PM  
May-10-18 07:18AM  
May-08-18 07:29PM  
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epstein David RDirectorDec 11Buy6.667,70051,26117,700Dec 14 05:15 PM
Liu Xiaoli JacquelinePrincipal Accounting OfficerDec 01Sale5.173,00015,5100Dec 02 04:44 PM
Epstein David RDirectorAug 31Buy4.495,75225,80410,000Sep 01 04:13 PM
Epstein David RDirectorAug 28Buy4.394,24818,6314,248Sep 01 04:13 PM
Flagship Ventures Fund IV Gene10% OwnerJun 29Buy3.754,666,66617,499,9984,079,032Jul 01 05:24 PM